Published in Clin Chim Acta on September 14, 1973
Characterization of jack-bean alpha-D-mannosidase as a zinc metalloenzyme. Biochem J (1975) 1.00
Multiple alpha-mannosidase activities in mammalian tissues as shown by metal-ion activation. Biochem J (1977) 0.97
Mannosidosis: assignment of the lysosomal alpha-mannosidase B gene to chromosome 19 in man. Proc Natl Acad Sci U S A (1977) 0.90
Immunoquantification and enzyme kinetics of alpha-L-iduronidase in cultured fibroblasts from normal controls and mucopolysaccharidosis type I patients. Am J Hum Genet (1992) 0.88
Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science (1991) 6.12
Lymphocyte suppression in leprosy induced by unique M. leprae glycolipid. Nature (1984) 2.63
Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med (1995) 2.30
A major T cell antigen of Mycobacterium leprae is a 10-kD heat-shock cognate protein. J Exp Med (1992) 1.93
Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clin Exp Immunol (1993) 1.88
Preliminary taxonomic studies on the leprosy bacillus. Br J Exp Pathol (1975) 1.83
Diffuse cutaneous leishmaniasis: a disease due to an immunological defect of the host. Trans R Soc Trop Med Hyg (1972) 1.69
Learning from lesions: patterns of tissue inflammation in leprosy. Proc Natl Acad Sci U S A (1988) 1.62
Elimination of Mycobacterium leprae subsequent to local in vivo activation of macrophages in lepromatous leprosy by other mycobacteria. Clin Exp Immunol (1974) 1.54
Circulating antibodies to mouse laminin in Chagas disease, American cutaneous leishmaniasis, and normal individuals recognize terminal galactosyl(alpha 1-3)-galactose epitopes. J Exp Med (1987) 1.49
Detection of antibodies toward secreted mycobacterial antigen 85 in untreated leprosy patients' sera. Int J Lepr Other Mycobact Dis (1999) 1.41
Immunotherapy with a mixture of Mycobacterium leprae and BCG in different forms of leprosy and in Mitsuda-negative contacts. Int J Lepr Other Mycobact Dis (1982) 1.41
Activated suppressor T cells in leprosy. J Immunol (1982) 1.37
A test for the determination of competency in clearing bacilli in leprosy patients. Bull World Health Organ (1972) 1.34
Identification of the noncultivable pathogenic mycobacteria M. leprae and M. lepraemurium. Int J Lepr Other Mycobact Dis (1968) 1.33
Physicochemical characteristics of the glycosaminoglycan-lysosomal enzyme interaction in vitro. A model of control of leucocytic lysosomal activity. Biochem J (1976) 1.33
Antibodies to laminin in American cutaneous leishmaniasis. Infect Immun (1984) 1.32
Characterization of Mycobacterium leprae cell wall-associated proteins with the use of T lymphocyte clones. J Immunol (1989) 1.29
HLA-linked control of predisposition to lepromatous leprosy. J Infect Dis (1985) 1.28
Trypanosoma cruzi: allopurinol in the treatment of mice with experimental acute Chagas disease. Exp Parasitol (1981) 1.27
Immunological changes observed in indeterminate and lepromatous leprosy patients and Mitsuda-negative contacts after the inoculation of a mixture of Mycobacterium leprae and BCG. Clin Exp Immunol (1979) 1.26
ELECTRON MICROSCOPE STUDY OF MYCOBACTERIUM LEPRAE AND ITS ENVIRONMENT IN A VESICULAR LEPROUS LESION. J Bacteriol (1962) 1.25
Diagnosis of cutaneous leishmaniasis and species discrimination of parasites by PCR and hybridization. J Clin Microbiol (1994) 1.24
Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet (1987) 1.24
Studies on human polymorphonuclear leukocyte enzymes. I. Assay of acid hydrolases and other enzymes. Biochim Biophys Acta (1973) 1.21
Serum levels of tumor necrosis factor in patients with American cutaneous leishmaniasis. Biol Res (1993) 1.20
Trypanosoma cruzi: defined medium for continuous cultivation of virulent parasites. Exp Parasitol (1979) 1.20
Mycolic acids from "noncultivable" mycobacteria. Infect Immun (1974) 1.17
T-cell subpopulations, expression of interleukin-2 receptor, and production of interleukin-2 and gamma interferon in human American cutaneous leishmaniasis. J Clin Microbiol (1988) 1.17
Immunological significance of Mycobacterium leprae cell walls. Proc Natl Acad Sci U S A (1988) 1.15
Lymphocyte transformation with phytomitogens in leprosy. Int J Lepr Other Mycobact Dis (1972) 1.15
Inhibition of leucocytic lysosomal enzymes by glycosaminoglycans in vitro. Biochem J (1975) 1.15
In situ characterization of the cellular immune response in American cutaneous leishmaniasis. Clin Exp Immunol (1985) 1.13
Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. Br J Dermatol (2007) 1.13
The Rac1 splice form Rac1b promotes K-ras-induced lung tumorigenesis. Oncogene (2012) 1.13
Immunological suppression by human CD8+ T cells is receptor dependent and HLA-DQ restricted. Proc Natl Acad Sci U S A (1991) 1.12
Studies on human polymorphonuclear leukocyte enzymes. II. Comparative study of the physical properties of primary and specific granules. Biochim Biophys Acta (1973) 1.11
Ganglion cysts associated with cruciate ligaments of the knee: a possible cause of recurrent knee pain. Acta Orthop Belg (2000) 1.09
The surface membrane of Leishmania. I. The effects of lectins on different stages of Leishmania braziliensis. J Parasitol (1975) 1.09
Leprosy: confirmation in the armadillo. Science (1974) 1.05
Ethics of HIV trials. Lancet (1997) 1.04
IgM antibodies to native phenolic glycolipid-I in contacts of leprosy patients in Venezuela: epidemiological observations and a prospective study of the risk of leprosy. Int J Lepr Other Mycobact Dis (1991) 1.02
IGF1 activates cell cycle arrest following irradiation by reducing binding of ΔNp63 to the p21 promoter. Cell Death Dis (2010) 1.01
Ectopic skin lesions produced by Schistosoma mansoni. Am J Trop Med Hyg (1973) 1.00
Studies on plating efficiency and estimation of viability of suspensions of Paracoccidioides brasiliensis yeast cells. Mycopathologia (1980) 1.00
Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. I: Skin-test reactivity, T-cell proliferation and interferon-gamma production. Vaccine (1994) 0.98
Results of a double blind study of the influence of thalidomide on the lepra reaction. Int J Lepr Other Mycobact Dis (1970) 0.98
Vaccination in leprosy--observations and interpretations. Int J Lepr Other Mycobact Dis (1980) 0.96
The Kellersberger Memorial Lecture: leprosy and leishmaniasis similar clinical-immunological-pathological models. Ethiop Med J (1974) 0.95
Antibodies to basement membrane protein nidogen in Chagas' disease and American cutaneous leishmaniasis. J Clin Microbiol (1986) 0.94
Fabry's disease: normal alpha-galactosidase activity and urinary-sediment glycosphingolipid levels in two obligate heterozygotes. Br J Dermatol (1973) 0.93
Intermediate or chronic cutaneous leishmaniasis: leukocyte immunophenotypes and cytokine characterisation of the lesion. Exp Dermatol (2002) 0.93
A simple method for the differentiation of Mycobacterium leprae from other mycobacteria through routine staining technics. Int J Lepr Other Mycobact Dis (1973) 0.92
Effect of allopurinol on different strains of Trypanosoma cruzi. Am J Trop Med Hyg (1981) 0.91
Delayed-type hypersensitivity and immunoglobulin E in American cutaneous leishmaniasis. Infect Immun (1982) 0.91
The development of a vaccination model using two microorganisms and its application in leprosy and leishmaniasis. Lepr Rev (1986) 0.91
Canine visceral leishmaniasis on Margarita Island (Nueva Esparta, Venezuela). Trans R Soc Trop Med Hyg (2000) 0.90
Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients. Parasite Immunol (2000) 0.90
Sinefungin as treatment for American Leishmania in sensitive BALB/c and resistant C57BL/6 mice. Am J Trop Med Hyg (1990) 0.90
Comparative effects of 4-aminopyrazolopyrimidine, its 2'-deoxyriboside derivative, and allopurinol on in vitro growth of American Leishmania species. Antimicrob Agents Chemother (1982) 0.90
Trypanosoma cruzi and American Leishmania spp: immunocytochemical localization of a laminin-like protein in the plasma membrane. Exp Parasitol (1986) 0.90
Differing antibody IgG isotypes in the polar forms of leprosy and cutaneous leishmaniasis characterized by antigen-specific T cell anergy. Clin Exp Immunol (1995) 0.90
Specificity of the 48-hour reaction to Mitsuda antigen. Use of a soluble antigen from human and armadillo lepromin. Bull World Health Organ (1975) 0.90
Serological and immunohistological studies on lepromatous leprosy. Int Arch Allergy Appl Immunol (1981) 0.88
Differential metabolism of allopurinol and derivatives in Trypanosoma rangeli and T. cruzi culture forms. Mol Biochem Parasitol (1981) 0.88
Some considerations regarding the immunology of leprosy. Int J Lepr Other Mycobact Dis (1972) 0.88
The effect of fresh serum on the leptomonads of Leishmania. I. Preliminary report. Trans R Soc Trop Med Hyg (1968) 0.88
Defect of in vitro digestive ability of polymorphonuclear leukocytes in paracoccidioidomycosis. Infect Immun (1980) 0.88
Immunocytochemical characterization of immune cells in lesions of American cutaneous leishmaniasis using novel T cell markers. Acta Trop (1991) 0.87
Antibodies to laminin in Trypanosoma rangeli-infected subjects. Parasitol Res (1987) 0.87
Specific IgG antibody responses may be used to monitor leprosy treatment efficacy and as recurrence prognostic markers. Eur J Clin Microbiol Infect Dis (2011) 0.87
Heterogeneity of acid phosphatase activity in human polymorphonuclear leukocytes. Clin Chim Acta (1973) 0.87
Immune response in healthy volunteers vaccinated with BCG plus killed leishmanial promastigotes: antibody responses to mycobacterial and leishmanial antigens. Vaccine (1994) 0.87
Recent advances in the immunology of leprosy. Int J Dermatol (1976) 0.85
Leishmania braziliensis causing visceral leishmaniasis in a patient with human immunodeficiency virus infection, identified with the aid of the polymerase chain reaction. Trans R Soc Trop Med Hyg (1994) 0.85
Polymorphonuclear activation in leprosy. I. Spontaneous and endotoxin-stimulated reduction of nitroblue tetrazolium: effects of serum and plasma on endotoxin-induced activation. Clin Exp Immunol (1975) 0.85
The influence of the type of sulphate bond and degree of sulphation of glycosaminoglycans on their interaction with lysosomal enzymes. Biochem J (1978) 0.85
Immunological reactions in onchocerciasis. Trans R Soc Trop Med Hyg (1970) 0.85
A study of antibody response in leprosy. Int J Lepr Other Mycobact Dis (1969) 0.84
Spheroidal bodies and globi of human leprosy. Biochem Biophys Res Commun (1973) 0.84
Study of the antibody response against Mycobacterium tuberculosis antigens in Warao Amerindian children in Venezuela. Mem Inst Oswaldo Cruz (2004) 0.84
Association of HLA specificity LB-E12 (MB1, DC1, MT1) with lepromatous leprosy in a Venezuelan population. Tissue Antigens (1984) 0.84
Acid and neutral hydrolases in Trypanosoma cruzi. Characterization and assay. J Protozool (1979) 0.84
Cell-mediated immunity in localized cutaneous leishmaniasis patients before and after treatment with immunotherapy or chemotherapy. Parasite Immunol (1989) 0.83
Differences in allopurinol and 4-aminopyrazolo(3,4-d) pyrimidine metabolism in drug-sensitive and insensitive strains of Trypanosoma cruzi. Mol Biochem Parasitol (1984) 0.83
Isolation of Leishmania infantum, zymodeme MON-1 from canine and human visceral leishmaniasis on Margarita Island, Venezuela. Mem Inst Oswaldo Cruz (2001) 0.82
Applying the indirect immunofluorescency test to the study of American cutaneous leishmaniasis. Dermatol Int (1969) 0.82
Mononuclear cell subpopulations and infiltrating lymphocytes in erythema dyschromicum perstans and vitiligo. Histol Histopathol (1987) 0.82
Immunotherapy and immunoprophylaxis of leprosy. Lepr Rev (1983) 0.82
The cutaneous lesion in American leishmaniasis: leukocyte subsets, cellular interaction and cytokine production. Biol Res (1993) 0.82